Grant News
A new funding opportunity has been launched by Blood Cancer UK to support innovative, large-scale clinical trials targeting the most challenging forms of blood cancer. The Strategic Clinical Trials Call aims to fund adaptable trials—such as multi-arm, multi-stage designs—that can significantly improve survival rates for people diagnosed with blood cancers that currently have a predicted five-year survival rate below 50%.
Eligible applicants can apply for grants ranging from £4 million to £8 million, with the maximum funding capped at £8 million per project. Projects must test novel treatments or treatment combinations, enhance treatment sequencing or scheduling, or offer more personalised approaches, such as the use of predictive or prognostic biomarkers. Applications must also include inclusive recruitment strategies to ensure representation across affected subgroups, and demonstrate a clear pathway to transforming clinical practice.
The scheme is open to organisations capable of delivering large-scale clinical trials, and is specifically intended for studies with the potential for paradigm-shifting impact. Smaller-scale trials should instead apply to Blood Cancer UK’s Transformational Research Awards. Interested parties must first submit an Expression of Interest (EOI) by the 26th June 2025. If shortlisted, full applications must be submitted by 3pm on the1st October 2025 via Grant Tracker.
To support applicants, a webinar will be held on the 2nd April 2025, followed by an in-depth workshop on the 20th May 2025. Both events aim to guide potential applicants through the complexities of trial design and submission.
Useful Links: